open access

Vol 62, No 2 (2011)
Original papers
Published online: 2011-04-29
Submitted: 2013-02-15
Get Citation

Angiotensin II as a factor modulating protein tyrosine kinase activity in two breast cancer lines — MCF-7 and MDA-MB-231

Urszula Lewandowska, Agnieszka Lachowicz-Ochędalska, Kamila Domińska, Dominika Kaszewska, Elżbieta Rębas
Endokrynologia Polska 2011;62(2):151-158.

open access

Vol 62, No 2 (2011)
Original papers
Published online: 2011-04-29
Submitted: 2013-02-15

Abstract

Introduction: Angiotensin II (AngII), a peptide that regulates the water-electrolytic balance and blood pressure, is also known to influence cell proliferation. It can either induce cell growth, when binding to angiotensin type-I receptor, or trigger growth inhibition via angiotensin type-II receptor. AngII stimulates proliferation of some normal and tumour cell lines, e.g. pituitary, adrenal glands and breast cancer.
Material and methods: The aim of this study was to evaluate possible AngII effect on the growth of two breast cancer cell lines — hormone-dependent MCF-7 and hormone-independent MDA-MB-231. We measured tyrosine kinase activity as a potential proliferation marker. We also estimated the influence of 17b-oestradiolon AngII-induced changes.
Results: In the MDA-MB-231 line, AngII radically slowed the activity of tyrosine kinases and 17b-oestradiol only at a concentration of 10–6 M, while it enhanced the effect of angiotensin II at a concentration of 10–9 M. In MCF-7, Ang II had a strong inhibitory effect in the presence of oestradiol (10–6 M). Oestradiol alone decreased the activity of examined enzymes in both cell lines. AngII receptor type 1 was found in both studied lines, but type 2 only in MDA-MB-231.
Conclusions: Our results show that AngII can modulate tyrosine kinase activity in breast tumour cell lines.
(Pol J Endocrinol 2011; 62 (2): 151–157)

Abstract

Introduction: Angiotensin II (AngII), a peptide that regulates the water-electrolytic balance and blood pressure, is also known to influence cell proliferation. It can either induce cell growth, when binding to angiotensin type-I receptor, or trigger growth inhibition via angiotensin type-II receptor. AngII stimulates proliferation of some normal and tumour cell lines, e.g. pituitary, adrenal glands and breast cancer.
Material and methods: The aim of this study was to evaluate possible AngII effect on the growth of two breast cancer cell lines — hormone-dependent MCF-7 and hormone-independent MDA-MB-231. We measured tyrosine kinase activity as a potential proliferation marker. We also estimated the influence of 17b-oestradiolon AngII-induced changes.
Results: In the MDA-MB-231 line, AngII radically slowed the activity of tyrosine kinases and 17b-oestradiol only at a concentration of 10–6 M, while it enhanced the effect of angiotensin II at a concentration of 10–9 M. In MCF-7, Ang II had a strong inhibitory effect in the presence of oestradiol (10–6 M). Oestradiol alone decreased the activity of examined enzymes in both cell lines. AngII receptor type 1 was found in both studied lines, but type 2 only in MDA-MB-231.
Conclusions: Our results show that AngII can modulate tyrosine kinase activity in breast tumour cell lines.
(Pol J Endocrinol 2011; 62 (2): 151–157)
Get Citation

Keywords

angiotensin; breast cancer; MDA-MB-231; MCF-7; 17b-oestradiol; PTKs

About this article
Title

Angiotensin II as a factor modulating protein tyrosine kinase activity in two breast cancer lines — MCF-7 and MDA-MB-231

Journal

Endokrynologia Polska

Issue

Vol 62, No 2 (2011)

Pages

151-158

Published online

2011-04-29

Bibliographic record

Endokrynologia Polska 2011;62(2):151-158.

Keywords

angiotensin
breast cancer
MDA-MB-231
MCF-7
17b-oestradiol
PTKs

Authors

Urszula Lewandowska
Agnieszka Lachowicz-Ochędalska
Kamila Domińska
Dominika Kaszewska
Elżbieta Rębas

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl